NegroS, MartinA, AzuaraL, SanchezY, BarciaE. Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine N-butyl bromide: retrospective clinical evaluation. J Palliat Med, 2010; 13:273–277.
2.
NegroS, AzuaraML, SanchezY, ReyesR, BarciaE. Physical compatibility and in vivo evaluation of drug muxtures for subcutaneous infusion to cancer patients in palliative care. Sipport Care Cancer, 2002; 10:65–70.
3.
DrummondS. National survey of drug use in palliative care. Palliat Med, 1996; 10:119–124.
4.
GrassbyP, HutchingsL. Drug combinations in syringe drivers: The compatibility and stability of diamorphine with cyclizine and haloperidol. Palliat Med, 1997; 11:217–224.
5.
FawcettJP, WoodsDJ, MunasiriB, BecketG. Compatibility of cyclizine lactate and haloperidol lactate. Am J Hosp Pharm, 1994; 51:2292.
6.
SchneiderJJ, WilsonKM, RavenscroftPJ. A study of the osmolality and pH of subcutaneous drug infusion solutions. Aust J Hosp Pharm, 1997; 27:29–31.
7.
StewartJT, WarrenFW, KingDT, VenkatheshwaranTG, FoxJL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Hosp Pharm, 1998; 55:2630–2634.
8.
TrisselLA. Drug stability and compatibility issues in drug delivery. Cancer Bill, 1990; 42:393–98.
9.
RoseM, CurrowDC. The need for chemical compatibility studies of subcutaneous medication combinations used in palliative care. J Pain Palliat Care Pharmacother, 2009; 23:223–230.
